Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
Voyager Therapeutics, a biotechnology company, will report its Q3 2023 financial and operating results on November 6, 2023. A conference call and webcast will be held to review the results. Telephone participants can register in advance to receive a confirmation email with details on how to join the call. The webcast will be available on the Voyager website, and a replay will be available for at least 30 days.
10/30/2023 - 07:00 AM
CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023 financial and operating results after market close on Monday, November 6, 2023. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results.
To participate via telephone and join the call live, please register in advance here . Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com , and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.
About Voyager Therapeutics Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com .
Voyager Therapeutics ® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts Investors Investors@vygr.com
Media Peg Rusconiprusconi@vergescientific.com
When will Voyager Therapeutics report its Q3 2023 financial and operating results?
Voyager Therapeutics will report its Q3 2023 financial and operating results on November 6, 2023.
What will be discussed during the conference call and webcast?
The conference call and webcast will review Voyager Therapeutics' financial and operating results for Q3 2023.
How can I participate in the conference call?
To participate in the conference call, you can register in advance on the Voyager Therapeutics website and receive a confirmation email with details on how to join.
Where can I access the webcast?
The webcast will be available on the Investors section of the Voyager Therapeutics website at ir.voyagertherapeutics.com.
Will there be a replay of the conference call?
Yes, a replay of the conference call will be available on the Voyager Therapeutics website for at least 30 days after its completion.
VYGR Rankings
#801 Ranked by Stock Gains
VYGR Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Cambridge
About VYGR
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.